On September 7, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will present at the following healthcare conferences in September (Press release, UroGen Pharma, SEP 7, 2022, View Source [SID1234619148]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. Annual Global Investment Conference

Tuesday, September 13 at 10:30 a.m. ET
Ladenburg Thalmann Healthcare Conference

Analyst Discussion on Thursday, September 29 at 8:30 a.m. ET
Webcasts of both the H.C. Wainwright & Co. and Ladenburg Thalmann presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

On September 7, 2022 Amgen (NASDAQ:AMGN) reported that it will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) (Free ESMO Whitepaper) at 1:30 p.m. ET on Monday, Sept. 12, 2022 (Press release, Amgen, SEP 7, 2022, View Source [SID1234619147]). David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team, will discuss the data being presented from the LUMAKRAS (sotorasib) CodeBreaK 200 confirmatory Phase 3 study in non-small cell lung cancer and data from the full Phase 1b expansion cohort of LUMAKRAS in combination with Vectibix (panitumumab) in colorectal cancer. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

On September 7, 2022 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, reported it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time (Press release, Applied DNA Sciences, SEP 7, 2022, https://adnas.com/apdn-to-present-at-h-c-wainwright-24th-annual-global-investment-conference/ [SID1234619146]). The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied DNA’s CEO and Chairman of the Board of Directors, Dr. James A. Hayward, will present in person and provide an overview of the Company’s business during the presentation.

To listen to a livestream of the Company’s presentation, please click on the following link to register for the conference: Applied DNA presentation at the H.C. Wainwright 24th Annual Global Investment Conference

On September 7, 2022 NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that its senior management will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York City (Press release, NKMax America, SEP 7, 2022, View Source [SID1234619145]). Please see details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NKGen Biotech will also hold one-on-one investor meetings. To schedule a meeting, please contact your Baird representative.

On September 7, 2022 ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, reported that L1 Capital Global Opportunities Master Fund ("L1") has exercised Options over 3,000,000 new ordinary shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £150,000 (Press release, ImmuPharma, SEP 7, 2022, View Source [SID1234619144]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New Ordinary Shares and Admission

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company’s existing issued ordinary shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Tuesday 13 September 2022.

The New Ordinary Shares represent 0.90% of the Company’s enlarged issued share capital.

Total Shares in Issue

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company’s total issued share capital will consist of 333,403,115 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.